Myofibroblast-mediated mechanisms of pathological remodelling of the heart

Nature Reviews Cardiology

Volumn 10, Issue 1, 2013, Pages 15-26

  Weber, Karl T ^a   Sun, Yao ^a   Bhattacharya, Syamal K ^a   Ahokas, Robert A ^a   Gerling, Ivan C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CYTOSKELETON PROTEIN; DYSTROPHIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MYOGLOBIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARRHYTHMOGENESIS; CELL DEATH; CELL FUNCTION; CELL INTERACTION; CELL LOSS; CELL STRUCTURE; CELL SURVIVAL; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DETOXIFICATION; EXTRACELLULAR MATRIX; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART REMODELLING; HUMAN; HYDROLYSIS; HYPERALDOSTERONISM; INFLAMMATORY CELL; MACROPHAGE; MEMBRANE PERMEABILITY; MUSCULAR DYSTROPHY; MYOFIBROBLAST; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL DEATH; COLLAGEN; EXTRACELLULAR MATRIX; FIBROSIS; HEART DISEASES; HEART VENTRICLES; HUMANS; MYOCYTES, CARDIAC; MYOFIBROBLASTS; NECROSIS; PHENOTYPE; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84871796377     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.158     Document Type: Review

References (160)

1. Weber, K. T. Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 13, 1637-1652 (1989). (Pubitemid 19145564)
2. Laurent, G. J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol. 252, C1-C9 (1987).
3. Schmitt-Gräff, A., Desmoulière, A. & Gabbiani, G. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch. 425, 3-24 (1994). (Pubitemid 24295501)
4. Gerling, I. C. et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am. J. Physiol. Heart Circ. Physiol. 285, H813-H821 (2003). (Pubitemid 36885915)
5. Ahokas, R. A. et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ. Res. 93, e124-e135 (2003).
6. Harrison, D. G., Cai, H., Landmesser, U. & Griendling, K. K. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 4, 51-61 (2003). (Pubitemid 36790175)
7. Harrison, D. G., Marvar, P. J. & Titze, J. M. Vascular inflammatory cells in hypertension. Front. Physiol. 3, 128 (2012).
8. Coen, M., Gabbiani, G. & Bochaton-Piallat, M. L. Myofibroblast- mediated adventitial remodeling: an underestimated player in arterial pathology. Arterioscler. Thromb. Vasc. Biol. 31, 2391-2396 (2011).
9. Rosker, C., Salvarani, N., Schmutz, S., Grand, T. & Rohr, S. Abolishing myofibroblast arrhythmogeneicity by pharmacological ablation of alpha-smooth muscle actin containing stress fibers. Circ. Res. 109, 1120-1131 (2011).
10. Yue, L., Xie, J. & Nattel, S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 89, 744-753 (2011).
11. Jalil, J. E., Janicki, J. S., Pick, R., Abrahams, C. & Weber, K. T. Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ. Res. 65, 258-264 (1989). (Pubitemid 19194611)
12. Fidziańska, A., Bilińska, Z. T., Walczak, E., Witkowski, A. & Chojnowska, L. Autophagy in transition from hypertrophic cardiomyopathy to heart failure. J. Electron Microsc. (Tokyo) 59, 181-183 (2010).
13. Shang, F. & Taylor, A. Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free Radic. Biol. Med. 51, 5-16 (2011).
14. Rodriguez, J. E., Schisler, J. C., Patterson, C. & Willis, M. S. Seek and destroy: the ubiquitin\proteasome system in cardiac disease. Curr. Hypertens. Rep. 11, 396-405 (2009).
15. Cosper, P. F. & Leinwand, L. A. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 71, 1710-1720 (2011).
16. Beltrami, C. A. et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89, 151-163 (1994). (Pubitemid 24026485)
17. Factor, S. M. et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 17, 1343-1351 (1991).
18. Waller, T. A., Hiser, W. L., Capehart, J. E. & Roberts, W. C. Comparison of clinical and morphologic cardiac findings in patients having cardiac transplantation for ischemic cardiomyopathy, idiopathic dilated cardiomyopathy, and dilated hypertrophic cardiomyopathy. Am. J. Cardiol. 81, 884-894 (1998). (Pubitemid 28213993)
19. Schaper, J., Lorenz-Meyer, S. & Suzuki, K. The role of apoptosis in dilated cardiomyopathy. Herz 24, 219-224 (1999). (Pubitemid 29254662)
20. de Leeuw, N. et al. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl. Int. 14, 299-306 (2001). (Pubitemid 33021059)
21. Yoshikane, H. et al. Collagen in dilated cardiomyopathy-scanning electron microscopic and immunohistochemical observations. Jpn Circ. J. 56, 899-910 (1992).
22. Marijianowski, M. M., Teeling, P., Mann, J. & Becker, A. E. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J. Am. Coll. Cardiol. 25, 1263-1272 (1995).
23. Pearlman, E. S., Weber, K. T., Janicki, J. S., Pietra, G. G. & Fishman, A. P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab. Invest. 46, 158-164 (1982). (Pubitemid 12181056)
24. Huysman, J. A. N., Vliegen, H. W., Van der Laarse, A. & Eulderink, F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol. Res. Pract. 184, 577-581 (1989). (Pubitemid 19169093)
25. Rossi, M. A. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J. Hypertens. 16, 1031-1041 (1998). (Pubitemid 28367959)
26. Lopez, B., Gonzalez, A., Querejeta, R., Larman, M. & Diez, J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J. Am. Coll. Cardiol. 48, 89-96 (2006). (Pubitemid 43929208)
27. Krayenbuehl, H. P. et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79, 744-755 (1989). (Pubitemid 19100533)
28. Schwarz, F. et al. Myocardial structure and function in patients with aortic valve disease and their relation to postoperative results. Am. J. Cardiol. 41, 661-669 (1978). (Pubitemid 8311358)
29. Hein, S. et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107, 984-991 (2003). (Pubitemid 36258721)
30. Brooks, W. W., Shen, S. S., Conrad, C. H., Goldstein, R. H. & Bing, O. H. Transition from compensated hypertrophy to systolic heart failure in the spontaneously hypertensive rat: Structure, function, and transcript analysis. Genomics 95, 84-92 (2010).
31. O'Hanlon, R. et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56, 867-874 (2010).
32. Green, J. J., Berger, J. S., Kramer, C. M. & Salerno, M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc. Imaging 5, 370-377 (2012).
33. Weber, K. T. et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ. Res. 62, 757-765 (1988).
34. Chapman, D., Weber, K. T. & Eghbali, M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ. Res. 67, 787-794 (1990). (Pubitemid 20315010)
35. Borg, T. K., Sullivan, T. & Ivy, J. Functional arrangement of connective tissue in striated muscle with emphasis on cardiac muscle. Scanning Electron Microsc. 4, 1775-1784 (1982).
36. Robinson, T. F., Cohen-Gould, L. & Factor, S. M. Skeletal framework of mammalian heart muscle. Arrangement of inter-and pericellular connective tissue structures. Lab. Invest. 49, 482-498 (1983). (Pubitemid 13021742)
37. Robinson, T. F., Factor, S. M. & Sonnenblick, E. H. The hear t as a suction pump. Sci. Am. 254, 84-91 (1986).
38. Cooper, G. Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. Am. J. Physiol. Heart Circ. Physiol. 291, H1003-H1014 (2006).
39. Hoshijima, M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am. J. Physiol. Heart Circ. Physiol. 290, H1313-H1325 (2006).
40. Voelkel, T. & Linke, W. A. Conformation-regulated mechanosensory control via titin domains in cardiac muscle. Pflügers Arch. 462, 143-154 (2011).
41. Streeter, D. D., Spotnitz, H. M., Patel, D. P., Ross, J. & Sonnenblick, E. H. Fiber orientation in the canine left ventricle during diastole and systole. Circ. Res. 24, 339-347 (1969).
42. Robinson, T. F., Geraci, M. A., Sonnenblick, E. H. & Factor, S. M. Coiled perimysial fibers of papillary muscle in rat heart: morphology, distribution, and changes in configuration. Circ. Res. 63, 577-592 (1988).
43. Robinson, T. F., Cohen-Gould, L., Factor, S. M., Eghbali, M. & Blumenfeld, O. O. Structure and function of connective tissue in cardiac muscle: collagen types I and III in endomysial struts and pericellular fibers. Scanning Microsc. 2, 1005-1015 (1988).
44. Lerman, R. H. et al. Myocardial healing and repair after experimental infarction in the rabbit. Circ. Res. 53, 378-388 (1983). (Pubitemid 13012420)
45. Jugdutt, B. I. Left ventricular rupture threshold during the healing phase after myocardial infarction in the dog. Can. J. Physiol. Pharmacol. 65, 307-316 (1987). (Pubitemid 17068302)
46. Factor, S. M., Robinson, T. F., Dominitz, R. & Cho, S. H. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. Am. J. Cardiovasc. Pathol. 1, 91-97 (1987).
47. Spinale, F. G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90, 520-530 (2002). (Pubitemid 34640901)
48. Zhao, M. J. et al. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. J. Am. Coll. Cardiol. 10, 1322-1334 (1987).
49. Rushmer, R. F. & Thal, N. The mechanics of ventricular contraction; a cinefluorographic study. Circulation 4, 219-228 (1951).
50. Fleckenstein, A., Frey, M. & Fleckenstein-Grun, G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur. Heart J. 4, 43-50 (1983). (Pubitemid 14211228)
51. Borkowski, B. J., Cheema, Y., Shahbaz, A. U., Bhattacharya, S. K. & Weber, K. T. Cation dyshomeostasis and cardiomyocyte necrosis. The Fleckenstein hypothesis revisited. Eur. Heart J. 32, 1846-1853 (2011).
52. Khan, M. U. et al. Mitochondria play a central role in nonischemic cardiomyocyte necrosis: common to acute and chronic stressor states. Pflügers Arch. 464, 123-131 (2012).
53. Garcia-Dorado, D., Ruiz-Meana, M., Inserte, J., Rodriguez-Sinovas, A. & Piper, H. M. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc. Res. 94, 168-180 (2012).
54. Palmieri, G. M., Nutting, D. F., Bhattacharya, S. K., Bertorini, T. E. & Williams, J. C. Parathyroid ablation in dystrophic hamsters. Effects on Ca content and histology of heart, diaphragm, and rectus femoris. J. Clin. Invest. 68, 646-654 (1981).
55. 2+ signalling and reactive oxygen species-generating pathways. Cardiovasc. Res. 77, 766-773 (2008). (Pubitemid 351301866)
56. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002). (Pubitemid 34303674)
57. Cleutjens, J. P. M., Kandala, J. C., Guarda, E., Guntaka, R. V. & Weber, K. T. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol. 27, 1281-1292 (1995).
58. Sun, Y., Zhang, J., Zhang, J. Q. & Weber, K. T. Renin expression at sites of repair in the infarcted rat heart. J. Mol. Cell. Cardiol. 33, 995-1003 (2001). (Pubitemid 32545333)
59. Sun, Y., Cleutjens, J. P. M., Diaz-Arias, A. A. & Weber, K. T. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc. Res. 28, 1423-1432 (1994). (Pubitemid 24300449)
60. Sun, Y. & Weber, K. T. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc. Res. 31, 518-525 (1996). (Pubitemid 26140062)
61. Sun, Y., Zhang, J. Q., Zhang, J. & Ramires, F. J. A. Angiotensin II, transforming growth factor-β1 and repair in the infarcted heart. J. Mol. Cell. Cardiol. 30, 1559-1569 (1998). (Pubitemid 28418646)
62. Horiguchi, M., Ota, M. & Rifkin, D. B. Matrix control of transforming growth factor-β function. J. Biochem. 152, 321-329 (2012).
63. Filip, D. A., Radu, A. & Simionescu, M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ. Res. 59, 310-320 (1986). (Pubitemid 17178125)
64. Katwa, L. C. et al. Valvular interstitial cells express angiotensinogen, cathepsin D, and generate angiotensin peptides. Int. J. Biochem. Cell Biol. 28, 807-821 (1996). (Pubitemid 26181830)
65. Bondi, C. D. et al. NAD(P)H oxidase mediates TGF-β1-induced activation of kidney myofibroblasts. J. Am. Soc. Nephrol. 21, 93-102 (2010).
66. Barker, T. H. et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 280, 36483-36493 (2005). (Pubitemid 41633922)
67. Cleutjens, J. P. M., Verluyten, M. J. A., Smits, J. F. M. & Daemen, M. J. A. P. Collagen remodeling after myocardial infarction in the rat heart. Am. J. Pathol. 147, 325-338 (1995).
68. Chapman, D. & Eghbali, M. Expression of fibrillar types I and III and basement membrane collagen type IV genes in myocardium of tight skin mouse. Cardiovasc. Res. 24, 578-583 (1990). (Pubitemid 20220921)
69. Whittaker, P. Unravelling the mysteries of collagen and cicatrix after myocardial infarction. Cardiovasc. Res. 31, 19-27 (1996).
70. Fomovsky, G. M., Rouillard, A. D. & Holmes, J. W. Regional mechanics determine collagen fiber structure in healing myocardial infarcts. J. Mol. Cell. Cardiol. 52, 1083-1090 (2012).
71. Sun, Y., Kiani, M. F., Postlethwaite, A. E. & Weber, K. T. Infarct scar as living tissue. Basic Res. Cardiol. 97, 343-347 (2002).
72. van den Borne, S. W. et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 30-37 (2010).
73. 1 and repair in the infarcted heart. J. Mol. Cell. Cardiol. 30, 1559-1569 (1998). (Pubitemid 28418646)
74. Sun, Y. & Weber, K. T. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J. Lab. Clin. Med. 127, 94-101 (1996). (Pubitemid 126690992)
75. Sun, Y., Ramires, F. J. A., Zhou, G., Ganjam, V. K. & Weber, K. T. Fibrous tissue and angiotensin II. J. Mol. Cell. Cardiol. 29, 2001-2012 (1997). (Pubitemid 27348513)
76. Katwa, L. C. et al. Pouch tissue and angiotensin peptide generation. J. Mol. Cell. Cardiol. 30, 1401-1413 (1998). (Pubitemid 28345041)
77. Sun, Y. et al. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J. Lab. Clin. Med. 143, 41-51 (2004). (Pubitemid 38156415)
78. Sun, Y. & Weber, K. T. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J. Lab. Clin. Med. 122, 404-411 (1993). (Pubitemid 23346775)
79. Katwa, L. C. et al. Cultured myofibroblasts generate angiotensin peptides de novo. J. Mol. Cell. Cardiol. 29, 1375-1386 (1997). (Pubitemid 27259651)
80. Campbell, S. E. & Katwa, L. C. Angiotensin II stimulated expression of transforming growth factor-beta 1 in cardiac fibroblasts and myofibroblasts. J. Mol. Cell. Cardiol. 29, 1947-1958 (1997). (Pubitemid 27303099)
81. Wang, Q. et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4, 4 (2011).
82. Arnott, J. A. et al. Molecular requirements for induction of CTGF expression by TGF-β1 in primary osteoblasts. Bone 42, 871-885 (2008).
83. Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008). (Pubitemid 351160157)
84. Ye, H., Cai, P. C., Zhou, Q. & Ma, W. L. Transforming growth factor-β1 suppresses the up-regulation of matrix metalloproteinase-2 by lung fibroblasts in response to tumor necrosis factor-α. Wound Repair Regen. 19, 392-399 (2011).
85. Willems, I. E. M. G., Havenith, M. G., De Mey, J. G. R. & Daemen, M. J. A. P. The α-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 145, 868-875 (1994).
86. Follonier Castella, L., Gabbiani, G., McCulloch, C. A. & Hinz, B. Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp. Cell Res. 316, 2390-2401 (2010).
87. Cotran, R. S., Kumar, V. & Robbins, S. L. in Robbins Pathologic Basis of Disease (eds Cotran, R. S., Kumar, V. & Robbins, S. L.) 597-656 (W. B. Saunders, Philadelphia, 1989).
88. Choudhury, L. et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 40, 2156-2164 (2002). (Pubitemid 36005903)
89. Maron, B. J., Epstein, S. E. & Roberts, W. C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am. J. Cardiol. 43, 1086-1102 (1979). (Pubitemid 9190990)
90. Finsterer, J. & Stöllberger, C. The heart in human dystrophinopathies. Cardiology 99, 1-19 (2003). (Pubitemid 36206630)
91. Swynghedauw, B. Molecular Cardiology for the Cardiologist (Kluwer, Boston, 1995).
92. Campbell, S. E., Rakusan, K. & Gerdes, A. M. Change in cardiac myocyte size distribution in aortic-constricted neonatal rats. Basic Res. Cardiol. 84, 247-258 (1989). (Pubitemid 19166433)
93. Pandya, K., Kim, H. S. & Smithies, O. Fibrosis, not cell size, delineates β-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc. Natl Acad. Sci. USA 103, 16864-16869 (2006). (Pubitemid 44737344)
94. López, J. E. et al. β-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ. Res. 109, 629-638 (2011).
95. López, B., Querejeta, R., González, A., Larman, M. & Díez, J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 60, 677-683 (2012).
96. Diez, J., Lopez, B., Gonzalez, A. & Querejeta, R. Clinical aspects of hypertensive myocardial fibrosis. Curr. Opin. Cardiol. 16, 328-335 (2001). (Pubitemid 33135220)
97. Weber, K. T., Brilla, C. G. & Janicki, J. S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res. 27, 341-348 (1993). (Pubitemid 23116130)
98. Bing, O. H. L., Fanburg, B. L., Brooks, W. W. & Matsushita, S. The effect of the lathyrogen β-amino proprionitrile (BAPN) on the mechanical properties of experimentally hypertrophied rat cardiac muscle. Circ. Res. 43, 632-637 (1978). (Pubitemid 9022308)
99. Westermann, D. et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 4, 44-52 (2011).
100. Martos, R. et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115, 888-895 (2007). (Pubitemid 46294729)
101. Gabbiani, G., Ryan, G. B. & Majno, G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27, 549-550 (1971).
102. Lorell, B. H. Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin II: current concepts. Basic Res. Cardiol. 87 (Suppl. 2), 163-172 (1992). (Pubitemid 23081266)
103. Friedrich, S. P. et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 90, 2761-2771 (1994).
104. Karagueuzian, H. S. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am. J. Cardiovasc. Dis. 1, 101-109 (2011).
105. Hothi, S. S. et al. Epac activation, altered calcium homeostasis and ventricular arrhythmogenesis in the murine heart. Pflügers Arch. 457, 253-270 (2008).
106. Rohr, S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm 6, 848-856 (2009).
107. Polyakova, V., Miyagawa, S., Szalay, Z., Risteli, J. & Kostin, S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J. Cell. Mol. Med. 12, 189-208 (2008).
108. Kallergis, E. M. et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J. Am. Coll. Cardiol. 52, 211-215 (2008). (Pubitemid 351915782)
109. Weber, K. T., Janicki, J. S. & Fishman, A. P. Aerobic limit of the heart perfused at constant pressure. Am. J. Physiol. 238, H118-H125 (1980).
110. Brilla, C. G., Janicki, J. S. & Weber, K. T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83, 1771-1779 (1991).
111. Youn, H. J. et al. Relation between flow reserve capacity of penetrating intramyocardial coronary arteries and myocardial fibrosis in hypertension: study using transthoracic Doppler echocardiography. J. Am. Soc. Echocardiogr. 19, 373-378 (2006).
112. Warnes, C. A., Maron, B. J. & Roberts, W. C. Massive cardiac ventricular scarring in first-degree relatives with hypertrophic cardiomyopathy. Am. J. Cardiol. 54, 1377-1379 (1984). (Pubitemid 15220579)
113. Maron, B. J., Wolfson, J. K., Epstein, S. E. & Roberts, W. C. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 8, 545-557 (1986). (Pubitemid 16048006)
114. Olivotto, I. et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J. Am. Coll. Cardiol. 58, 839-48 (2011).
115. Weber, K. T., Jalil, J. E., Janicki, J. S. & Pick, R. Myocardial collagen remodeling in pressure overload hypertrophy: a case for interstitial heart disease. Am. J. Hypertens. 2, 931-940 (1989). (Pubitemid 20046711)
116. Collier, P., Ledwidge, M. & McDonald, K. Diagnostics and therapeutic interventions in myocardial interstitial disease, a previously neglected pathology. QJM 105, 721-724 (2012).
117. Griffiths, E. J. Mitochondria and heart disease. Adv. Exp. Med. Biol. 942, 249-267 (2012).
118. Dai, D. F. et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J. Am. Coll. Cardiol. 58, 73-82 (2011).
119. Shahbaz, A. U. et al. Mitochondria-targeted cardioprotection in aldosteronism. J. Cardiovasc. Pharmacol. 57, 37-43 (2011).
120. Cheema, Y. et al. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J. Cardiovasc. Pharmacol. 58, 80-86 (2011).
121. ATP channels and permeability transition pores of mitochondria in dogs. Cardiovasc. Drugs Ther. 26, 217-226 (2012).
122. 2+ overload and cell death. J. Clin. Invest. 122, 1222-1232 (2012).
123. Bauersachs, J. Regulation of myocardial fibrosis by MicroRNAs. J. Cardiovasc. Pharmacol. 56, 454-459 (2010).
124. Thum, T. & Lorenzen, J. M. Cardiac fibrosis revisited by microRNA therapeutics. Circulation 126, 800-802 (2012).
125. Gieling, R. G., Burt, A. D. & Mann, D. A. Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin. Liver Dis. 12, 915-937 (2008).
126. Elsharkawy, A. M., Oakley, F. & Mann, D. A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10, 927-939 (2005). (Pubitemid 41285572)
127. Muddu, A. K., Guha, I. N., Elsharkawy, A. M. & Mann, D. A. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int. J. Biochem. Cell Biol. 39, 695-714 (2007). (Pubitemid 46366796)
128. Smits, J. F. M., van Krimpen, C., Schoemaker, R. G., Cleutjens, J. P. M. & Daemen, M. J. A. P. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J. Cardiovasc. Pharmacol. 20, 772-778 (1992).
129. Tsutsui, H. et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens. Res. 30, 439-449 (2007). (Pubitemid 46958894)
130. Matsusaka, H. et al. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J. Cardiovasc. Pharmacol. 48, 95-102 (2006). (Pubitemid 44562948)
131. Iwamoto, M. et al. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. Hypertens. Res. 33, 1305-1311 (2010).
132. Hoch, N. E. et al. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R208-R216 (2009).
133. Touyz, R. M. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol. 90, 449-55 (2005). (Pubitemid 40980144)
134. Fujiwara, Y. et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int. J. Mol. Med. 22, 703-708 (2008).
135. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121 (2006).
136. 1) receptor blockade. PLoS ONE 6, e23411 (2011).
137. Aksu, S. et al. Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leuk. Lymphoma 47, 891-896 (2006). (Pubitemid 43840646)
138. Haznedaroglu, I. C. & Beyazit, Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J. Renin Angiotensin. Aldosterone Syst. 11, 205-213 (2010).
139. Garcia, G. E. ANG II receptor antagonists as modulators of macrophages polarization. Am. J. Physiol. Renal Physiol. 298, F868-F869 (2010).
140. Rehman, A. et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59, 291-299 (2012).
141. Keidar, S., Kaplan, M. & Gamliel-Lazarovich, A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc. Res. 73, 463-469 (2007). (Pubitemid 46091776)
142. Zisman, L. S. et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108, 1707-1712 (2003). (Pubitemid 37243658)
143. Burrell, L. M. et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 26, 369-375; discussion 322-324 (2005). (Pubitemid 40283096)
144. Takeda, Y. et al. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 20, 1119-1124 (2007). (Pubitemid 47446168)
145. Sukumaran, V. et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int. J. Biol. Sci. 7, 1077-1092 (2011).
146. Kassiri, Z. et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2, 446-455 (2009).
147. Zhao, Y. X. et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum. Gene Ther. 21, 1545-1554 (2010).
148. Dong, B. et al. Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 59, 739-747 (2012).
149. Trask, A. J. et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am. J. Hypertens. 23, 687-693 (2010).
150. Liu, X., Hu, H. & Yin, J. Q. Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis. Liver Int. 26, 8-22 (2006).
151. Yang, F., Chung, A. C., Huang, X. R. & Lan, H. Y. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-β-dependent and-independent Smad pathways: the role of Smad3. Hypertension 54, 877-884 (2009).
152. Lan, H. Y. Transforming growth factor-β/Smad signalling in diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 39, 731-738 (2012).
153. Hinz, B. et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340-1355 (2012).
154. Hawinkels, L. J. & Ten Dijke, P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 29, 140-152 (2011).
155. Bauersachs, J. Regulation of myocardial fibrosis by MicroRNAs. J. Cardiovasc. Pharmacol. 56, 454-459 (2010).
156. Guntaka, R. V., Varma, B. R. & Weber, K. T. Triplex-forming oligonucleotides as modulators of gene expression. Int. J. Biochem. Cell Biol. 35, 22-31 (2003). (Pubitemid 35449170)
157. Koilan, S. et al. Prevention of liver fibrosis by triple helix-forming oligodeoxyribonucleotides targeted to the promoter region of type I collagen gene. Oligonucleotides 20, 231-237 (2010).
158. Brilla, C. G., Funck, R. C. & Rupp, H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102, 1388-1393 (2000).
159. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35, 1197-1202 (2000). (Pubitemid 30413650)
160. Díez, J. et al. Losar tan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105, 2512-2517 (2002). (Pubitemid 34568973)